Research advances in treatment of primary biliary cholangitis

VernacularTitle:原发性胆汁性胆管炎的治疗进展
Author: Yanmei LI ¹ ; Qixia WANG ; Xiong MA
Author Information

1. Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200001, China
Publication Type:Research Article
Keywords: liver cirrhosis, biliary; ursodeoxycholic acid; therapy
From: Journal of Clinical Hepatology 2016;32(8):1491-1496
CountryChina
Language:Chinese
Abstract: Primary biliary cholangitis (PBC) is an autoimmune liver disease mainly involving intrahepatic interlobular bile ducts and can progress to liver fibrosis, cirrhosis, and even liver failure. At present, the only drug approved for the treatment of PBC is ursodeoxycholic acid (UDCA), but up to 40% of PBC patients have suboptimal response to UDCA, and the risk of related complications is increased. Nowadays, other drugs and treatment methods, such as fibrates, glucocorticoids, immunosuppressants, obeticholic acid, biological agents, and mesenchymal stem cells, have been gradually applied in clinical practice and have brought the hope for the treatment of these patients.